News | May 12, 2026
JB Chemicals reports muted Q4 FY26 as integration resets business
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The private funding rose 38% amid growing international collaborations and CDMO demand
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Marking three years of the National Diagnostics Catapult (NDxC), the conclave launched the Impact Report and unveiled environmental surveillance kits
The company allocated €56 million to research and development for next-generation line solutions
The company reported net revenue of SEK 13.5 million for the full year 2025
The reports will now be shared with relevant ministries and departments as a guidance framework
Subscribe To Our Newsletter & Stay Updated
